Incorporating the TBX2 signature into the PAC outcome data showed that, in the low TBX2 expression subgroup, patients with PAC had greater RFS and OS benefit than patients without PAC (Fig. 4A-B, log rank test p =0.025 and p=0.014, respectively). This evidence concerns the gene TBX2 and gonorrhea.